bioRxivMicrobiology
Antibody repertoire induced by SARS-CoV-2 spike protein immunogens
S. Ravichandran, E. M. Coyle, L. Klenow, J. Tang, G. Grubbs, S. Liu, T. Wang, H. Golding, S. Khurana
Abstract
Multiple vaccine candidates against SARS-CoV-2 based on viral spike protein are under development. However, there is limited information on the quality of antibody response generated following vaccination by these vaccine modalities. To better understand antibody response induced by spike protein-based vaccines, we immunized rabbits with various SARS-CoV-2 spike protein antigens: S-ectodomain (S1+S2) (aa 16-1213), which lacks the cytoplasmic and transmembrane domains (CT-TM), the S1 domain (aa 16-685), the receptor-binding domain (RBD) (aa 319-541), and the S2 domain (aa 686-1213 as control). Antibody response was analyzed by ELISA, Surface Plasmon Resonance (SPR) against different Spike proteins in native conformation, and a pseudovirion neutralization assay to measure the quality and function of the antibodies elicited by the different Spike antigens. All three antigens (S1+S2 ectodomain, S1 domain, and RBD) generated strong neutralizing antibodies against SARS-CoV-2. Vaccination induced antibody repertoire was analyzed by SARS-CoV-2 spike Genome Fragment Phage Display Libraries (SARS-CoV-2 GFPDL), which identified immunodominant epitopes in the S1, S1-RBD and S2 domains. Furthermore, these analyses demonstrated that surprisingly the RBD immunogen elicited a higher antibody titer with 5-fold higher affinity antibodies to native spike antigens compared with other spike antigens. These findings may help guide rational vaccine design and facilitate development and evaluation of effective therapeutics and vaccines against COVID-19 disease. One Sentence SummarySARS-CoV-2 Spike induced immune response
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
- Limited variation between SARS-CoV-2-infected individuals in domain specificity and relative potency of the antibody response against the spike glycoprotein
H. A. Van Ert, D. W. Bohan, … H. Haim·bioRxiv·Aug 4, 2021
- A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
- Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike
L. Liu, P. Wang, … D. D. Ho·NaturePeer-reviewed·Jul 22, 2020
- Analysis of the SARS-CoV-2 spike protein revealed that blocked receptor-binding domain antigenicity decreases the production of neutralizing antibodies in vivo
Y.-F. Mei, Q. Zhang, … M. Landstrom·bioRxiv·Feb 23, 2023
- The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.
T. Steffen, E. T. Stone, … J. D. Brien·bioRxiv·Aug 21, 2020